Literature DB >> 18820867

Intratumoral expression of macrophage migration inhibitory factor is correlated with serum C-reactive protein and interleukin-6 in patients with non-small cell lung cancer.

Motoharu Hamatake1, Ichiro Yoshino, Makiko Tomiyasu, Naoko Miura, Hiroshi Okazaki, Taro Ohba, Tomohiro Takenaka, Yoshihiko Maehara.   

Abstract

PURPOSE: To investigate if macrophage migration inhibitory factor (MIF) affects systemic inflammatory response in patients with non-small cell lung cancer (NSCLC), we studied the relationship between intratumoral MIF expression and serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6).
METHODS: mRNAs for MIF and beta-actin, and 18S ribosomal RNA derived from tumor-bearing and nontumor-bearing tissues were quantified by a quantitative reverse transcription-polymerase chain reaction in 35 patients with NSCLC. Spearman's test was used to examine the correlation between the quantities of RNAs and the preoperative serum levels of CRP and IL-6 in the corresponding patients.
RESULTS: The intratumoral level of MIF mRNA was significantly correlated with the serum levels of CRP (rho = 0.542, P = 0.0016) and IL-6 (rho = 0.532, P = 0.0173). The level of MIF mRNA in the non-tumor-bearing lung also showed a positive, but relatively weak correlation with the serum CRP level (rho = 0.418, P = 0.0148).
CONCLUSION: Macrophage migration inhibitory factor expression in the tumor site may affect the systemic inflammatory response in patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820867     DOI: 10.1007/s00595-008-3765-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  24 in total

1.  Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer.

Authors:  M D Barber; K C Fearon; J A Ross
Journal:  Clin Sci (Lond)       Date:  1999-01       Impact factor: 6.124

2.  Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth.

Authors:  N Takahashi; J Nishihira; Y Sato; M Kondo; H Ogawa; T Ohshima; Y Une; S Todo
Journal:  Mol Med       Date:  1998-11       Impact factor: 6.354

3.  Acute phase reaction, heterogeneity, and microheterogeneity of serum proteins as nonspecific tumor markers in lung cancer.

Authors:  J E Hansen; J Iversen; A Lihme; T C Bøg-Hansen
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

4.  Dissociation between T helper type 1 and type 2 differentiation and cytokine production in tumor-infiltrating lymphocytes in patients with lung cancer.

Authors:  N Ito; H Nakamura; H Metsugi; S Ohgi
Journal:  Surg Today       Date:  2001       Impact factor: 2.549

5.  Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.

Authors:  F De Vita; M Orditura; A Auriemma; S Infusino; A Roscigno; G Catalano
Journal:  Oncol Rep       Date:  1998 May-Jun       Impact factor: 3.906

6.  Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases.

Authors:  K Meyer-Siegler; P B Hudson
Journal:  Urology       Date:  1996-09       Impact factor: 2.649

7.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

Authors:  V Rusch; J Baselga; C Cordon-Cardo; J Orazem; M Zaman; S Hoda; J McIntosh; J Kurie; E Dmitrovsky
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

8.  Identification of macrophage migration inhibitory factor (MIF) in human skin and its immmunohistochemical localization.

Authors:  T Shimizu; A Ohkawara; J Nishihira; W Sakamoto
Journal:  FEBS Lett       Date:  1996-03-04       Impact factor: 4.124

9.  MIF as a glucocorticoid-induced modulator of cytokine production.

Authors:  T Calandra; J Bernhagen; C N Metz; L A Spiegel; M Bacher; T Donnelly; A Cerami; R Bucala
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

10.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.

Authors:  T Calandra; J Bernhagen; R A Mitchell; R Bucala
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more
  3 in total

1.  Current status of and prospects for the English medical journal Surgery Today.

Authors:  Yoshihiko Maehara; Yoshihiro Kakeji
Journal:  Surg Today       Date:  2010-12       Impact factor: 2.549

2.  Correlation of macrophage migration inhibitory factor gene polymorphism with the risk of early-stage cervical cancer and lymphatic metastasis.

Authors:  Suhui Wu; Junfang Lian; Huijuan Tao; Haixia Shang; Li Zhang
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

3.  Natriuretic peptide receptor a as a novel target for prostate cancer.

Authors:  Xiaoqin Wang; Payal Raulji; Shyam S Mohapatra; Ronil Patel; Gary Hellermann; Xiaoyuan Kong; Pedro L Vera; Katherine L Meyer-Siegler; Domenico Coppola; Subhra Mohapatra
Journal:  Mol Cancer       Date:  2011-05-17       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.